Nav: Home

ESMO announces new award for achievements in immuno-oncology

February 09, 2017

Lugano, Feb. 9, 2017 - ESMO, the leading European professional organisation for medical oncology, has announced today a new award honouring individuals for outstanding achievements in the area of cancer immunotherapy.

"Immunotherapy is an exciting and rapidly evolving area in oncology. Recognising excellence in this emerging area is a duty and an honour for us, as the society of reference committed to improving outcomes for cancer patients," said ESMO President Fortunato Ciardiello.

The new ESMO Award for Immuno-Oncology is in memory of Professor Georges Mathé, a French oncologist and immunologist who performed the first bone marrow graft between unrelated donors in 1958.

"Georges Mathé was indeed a pioneer of immunotherapy but also one of the co-founders of ESMO in 1975, who had the vision that medical oncology would become one of the most exciting development areas for cancer medicine," said Christoph Zielinski, Chair of the ESMO Fellowship and Award Committee.

Immunotherapy, which engages the patient's own defences to fight cancer, has considerably changed the landscape of treatment options in the last few years. Professor Mathé worked in this field from the fifties to the eighties, anticipating the need of developing immunotherapy and applying it to cancer treatment.

"I am very proud that ESMO is honouring my father's achievements with this prestigious award, recognising the growing importance of immunotherapies applied to cancer care. As the descendant of one of ESMO's founders and immunotherapy pioneers, I am grateful for the appreciation of his work which has brought new hope for cancer patients," said Catherine Gaston-Mathé.

The first award will be presented at the ESMO Immuno-Oncology Congress in Geneva on 7 December 2017.

"ESMO has always maintained the visionary attitude of its founders," said Rolf A. Stahel, ESMO Past President and initiator of the ESMO immuno-oncology projects.

ESMO organised the very first educational meeting on the basics of immunology in 2007. In 2013 a series of smaller annual events dedicated to immune-oncology was started with the ESMO Symposium on Immuno-Oncology.

"In the light of recent developments, renewing our commitment to keeping oncologists up to date in such a rapidly evolving field, the now fully-fledged ESMO Immuno-Oncology Congress will be the ideal platform for all stakeholders interested in immunotherapy as a new way to treat cancer patients," Stahel said.

Basic, translational and clinical researchers, immunologists, oncology clinicians will be offered an expanded programme and focused sessions dedicated to different tumour types.

"From the basics of immunotherapies to the latest research results in different cancer types; from understanding different treatment options to management of toxicities and interpretation of new data, we aim to create the European community of immune-oncology stakeholders," said Stahel.

"Immunotherapy provides medical oncologists with another tool to treat cancer patients. The ESMO Immuno-Oncology Congress will help to increase the overall understanding of the potential of this therapy and its implications for clinical practice, today and in the future," said Professor George Coukos, Scientific Co-Chair of the congress, director of the Department of Oncology at the University Hospital of Lausanne (CHUV) and the Ludwig Cancer Research Centre, Lausanne, Switzerland.

"I think this is one of the most exciting fields to be working in today! There are very important developments in many disease types which could lead to a radical reduction in the relapse rate and therefore an increase in the cure of many cancers," explained Coukos.

"The launch of the ESMO Immuno-Oncology Congress together with the new award in memory of Georges Mathé reflects ESMO's commitment to help cancer physicians and researchers keep abreast of the latest developments in oncology, in an effort to bring innovative approaches to cancer patients," the ESMO President concluded.
-end-


European Society for Medical Oncology

Related Immunotherapy Articles:

Immunotherapy prior to surgery is effective in colon cancer
Patients with colon cancer, but no distant metastases, can benefit from a short course of immunotherapy while waiting for their surgery, as it can cause tumours to shrink substantially or clear up in a very short time.
Researchers discover potential boost to immunotherapy
Mount Sinai researchers have discovered a pathway that regulates special immune system cells in lung cancer tumors, suppressing them and allowing tumors to grow.
Predicting immunotherapy success
Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments.
Designer probiotic treatment for cancer immunotherapy
Columbia Engineers have engineered probiotics to safely deliver immunotherapies within tumors, including nanobodies against two proven therapeutic targets -- PD-L1 and CTLA-4.
Cancer vaccine could boost the effectiveness of immunotherapy
Supercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports.
Math models add up to improved cancer immunotherapy
A merger of math and medicine may help to improve the efficacy of immunotherapies, potentially life-saving treatments that enhance the ability of the patient's own immune system to attack cancerous tumors.
B cells linked to effective cancer immunotherapy
Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumors contained specific clusters of B cells, according to new research from Lund University in Sweden.
B cells: New allies in sarcoma immunotherapy?
How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer?
Transition to exhaustion: clues for cancer immunotherapy
Emory research on immune cells 'exhausted' by chronic viral infection provides clues on how to refine cancer immunotherapy.
Using artificial intelligence to determine whether immunotherapy is working
Currently, only about 20% of all cancer patients will actually benefit from costly immunotherapy.
More Immunotherapy News and Immunotherapy Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.